Effects of ultrasound on apoptosis induced by anti-CD20 antibody in CD20-positive B lymphoma cells

被引:10
作者
Danno, Daisuke [1 ]
Kanno, Masatoshi [1 ]
Fujimoto, Shinichi [1 ]
Feril, Loreto B., Jr. [2 ]
Kondo, Takashi [3 ]
Nakamura, Shinobu [1 ]
机构
[1] Nara Med Univ, Sch Med, Dept Gen Med, Kashihara, Nara 634, Japan
[2] Fukuoka Univ, Sch Med, Dept Anat, Fukuoka 81401, Japan
[3] Toyama Univ, Dept Radiol Sci, Grad Sch Med & Pharmaceut Sci, Toyama 930, Japan
关键词
ultrasound; rituximab; antigen-antibody reaction; immunotherapy; B-cell lymphoma;
D O I
10.1016/j.ultsonch.2007.08.004
中图分类号
O42 [声学];
学科分类号
070206 ; 082403 ;
摘要
Aim: The present study was conducted to examine the thermal and non-thermal effects of ultrasound on apoptosis induced by anti-CD20 monoclonal antibody (rituximab). Materials and methods: SU-DHL-4 cells, a CD20-positive cell line derived from B cell lymphomas with a BCL2 gene rearrangement, were exposed to continuous 1 MHz ultrasound for therapeutic use under an air- or CO2-saturated condition to control cavitation. Early apoptosis (EA) and secondary necrosis (SN) were examined by flow cytometry. Cavitation was determined by detecting the hydroxyl radicals derived from pyrolysis of water molecules using electron paramagnetic resonance-spin trapping. To assess thermal effects, cells were treated in a temperature-controlled water bath. Results: There was a significant additive increase in EA and EA + SN observed in cells treated with rituximab combined with heat at 42 degrees C or non-thermal ultrasound at 0.5 W/cm(2) under an air-saturated condition, where heat or ultrasound induced some cell death. A significant synergistic increase in EA and EA + SN was observed in cells treated with rituximab and ultrasound at 2.5 W/cm(2) under CO2-saturated conditions, where inertial cavitations were completely suppressed. No enhancement was observed at a temperature less than 40 degrees C or ultrasound at 0.5 W/cm2 under CO2-saturated conditions. Conclusion: These results suggest that the immuno-therapeutic application of ultrasound at relatively high-intensities combined with rituximab thus produces synergistic effects under conditions where the non-thermal and non-cavitational effects are predominant. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:463 / 471
页数:9
相关论文
共 50 条
[21]   Establishment of C20Mab-11, a novel anti-CD20 monoclonal antibody, for the detection of B cells [J].
Furusawa, Yoshikazu ;
Kaneko, Mika Kato ;
Kato, Yukinari .
ONCOLOGY LETTERS, 2020, 20 (02) :1961-1967
[22]   Role of anti-CD20 monoclonal antibody in association with immunomodulatory agents [J].
Bosly, A .
PATHOLOGIE BIOLOGIE, 2004, 52 (01) :39-42
[23]   Anti-CD20 monoclonal antibodies: Beyond B-cells [J].
Avivi, Irit ;
Stroopinsky, Dina ;
Katz, Tamar .
BLOOD REVIEWS, 2013, 27 (05) :217-223
[24]   MAb Therapy:: the use of anti-CD20 Abs -: In vitro and in vivo purging of B lymphoma cells from stem-cell products using anti-CD20 Abs [J].
Derigs, HG .
CYTOTHERAPY, 2000, 2 (06) :445-453
[25]   Anti-CD20 monoclonal antibodies: reviewing a revolution [J].
Casan, J. M. L. ;
Wong, J. ;
Northcott, M. J. ;
Opat, S. .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (12) :2820-2841
[26]   Molecular mechanisms of the antitumor effects of anti-CD20 antibodies [J].
Winiarska, Magdalena ;
Glodkowska-Mrowka, Eliza ;
Bil, Jacek ;
Golab, Jakub .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2011, 16 :277-306
[27]   Synergistic Effect of Dendritic Cell Vaccination and Anti-CD20 Antibody Treatment in the Therapy of Murine Lymphoma [J].
Gadri, Zohar ;
Kukulansky, Tova ;
Bar-Or, Eyal ;
Haimovich, Joseph ;
Hollander, Nurit .
JOURNAL OF IMMUNOTHERAPY, 2009, 32 (04) :333-340
[28]   Translational Medicine in Action: Anti-CD20 Therapy in Lymphoma [J].
Lim, Sean H. ;
Levy, Ronald .
JOURNAL OF IMMUNOLOGY, 2014, 193 (04) :1519-1524
[29]   Blocking the CD39/CD73 pathway synergizes with anti-CD20 bispecific antibody in nodal B-cell lymphoma [J].
Kolbe, Clara ;
Kauer, Joseph ;
Brinkmann, Berit ;
Dreger, Peter ;
Huber, Wolfgang ;
Mueller-Tidow, Carsten ;
Dietrich, Sascha ;
Roider, Tobias .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (01)
[30]   VELTUZUMAB Humanized Anti-CD20 Monoclonal Antibody Oncolytic [J].
Bhat, S. A. ;
Czuczman, M. S. .
DRUGS OF THE FUTURE, 2011, 36 (07) :519-526